Skip to main content

Advertisement

Log in

FDG positron emission tomography imaging of drug-induced pneumonitis

  • Case Report
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Several studies have reported the findings of fluorine-18-labeled fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in benign lung disease with diffuse pulmonary injury; however, the characteristics and effectiveness of FDG-PET imaging for interstitial pneumonitis have not been substantiated. We report two cases of drug-induced pneumonitis in two patients treated for breast cancer who were diagnosed by FDG-PET examination. Both the cases showed diffuse interstitial infiltration in the bilateral lungs on computed tomography, but the degree of FDG accumulation was different. It is probable that the degree of FDG accumulation reflected the activity of the drug-induced pneumonitis. The present cases show very interesting FDG-PET imaging findings of diffuse lung disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Higashi K, Matsunari I, Ueda Y, Ikeda R, Guo J, Oguchi M, et al. Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med 2003;17:1–14.

    Article  PubMed  Google Scholar 

  2. Laking G, Price P. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer. Thorax 2001;56Suppl 2:ii38–ii44.

    PubMed  Google Scholar 

  3. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 2004;34:313–329.

    Article  PubMed  Google Scholar 

  4. Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003;44:540–548.

    PubMed  CAS  Google Scholar 

  5. Tsujikawa T, Okazawa H, Tsuchida T, Demura Y, Imamura Y, Fujibayashi Y. A 18F-FDG-positive, 67Ga-negative, and transferrin receptor expression-negative patient with diffuse large B-cell lymphoma. Ann Nucl Med 2007;21:375–378.

    Article  PubMed  Google Scholar 

  6. Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006;47:1571–1576.

    PubMed  Google Scholar 

  7. Hassaballa HA, Cohen ES, Khan AJ, Ali A, Bonomi P, Rubin DB. Positron emission tomography demonstrates radiation-induced changes to nonirradiated lungs in lung cancer patients treated with radiation and chemotherapy. Chest 2005;128:1448–1452.

    Article  PubMed  Google Scholar 

  8. Meissner HH, Soo Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration 2006;73:197–202.

    PubMed  Google Scholar 

  9. Kirsch J, Arrossi AV, Yoon JK, Wu G, Neumann DR. FDG positron emission tomography/computerized tomography features of bleomycin-induced pneumonitis. J Thorac Imaging 2006;21:228–230.

    Article  PubMed  Google Scholar 

  10. White DA. Drugs and the lungs: comprehensive respiratory medicine, Chap. 77. St. Louis: Mosby; 1999. p. 20.

    Google Scholar 

  11. Fraser RS, Muller NL, Colman N, Pare P. Drugs. In: Fraser RS, Par JAP, editors. Fraser and Pare’s diagnosis of diseases of the chest. 4th ed. Philadelphia: WB Saunders; 1999. p. 2537–2583.

    Google Scholar 

  12. Miyata M, Sakuma F, Fukaya E, Kobayashi H, Rai T, Saito H, et al. Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis. Intern Med 2002;41:467–473.

    Article  PubMed  Google Scholar 

  13. Ishimori T, Saga T, Mamede M, Kobayashi H, Higashi T, Nakamoto Y, et al. Increased 18F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med 2002;43:658–663.

    PubMed  CAS  Google Scholar 

  14. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301–1306.

    PubMed  CAS  Google Scholar 

  15. Hansson L, Ohlsson T, Valind S, Sandell A, Luts A, Jeppsson B, et al. Glucose utilisation in the lungs of septic rats. Eur J Nucl Med 1999;26:1340–1344.

    Article  PubMed  CAS  Google Scholar 

  16. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91Suppl 2:S18–S23.

    Article  PubMed  CAS  Google Scholar 

  17. Camus P. Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br J Cancer 2004;91Suppl 2:S1–S2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Miwa Morikawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morikawa, M., Demura, Y., Mizuno, S. et al. FDG positron emission tomography imaging of drug-induced pneumonitis. Ann Nucl Med 22, 335–338 (2008). https://doi.org/10.1007/s12149-007-0109-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-007-0109-9

Keywords

Navigation